



Contra Costa Health Plan
P&T Formulary Update
March 1, 2024

Changes effective: 04/19/2024

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On March 1, 2024 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews
• Insulins • First generation antihistamines • Direct oral anticoagulants • Opioid containing antitussives • Vaccines • CDK 4-6 inhibitors • SGLT2 class review • ICS/LABA
Drug Monographs
• Casgevy monograph • Lyfgenia monograph • Methergine monograph
Prior Authorization Criteria Updates
<u>New criteria was created for the following agents:</u> • Casgevy (exagamglogene autotemcel) • Lyfgenia (lovotibeglogene autotemcel) • Ztildo <u>Updates were made to the criteria for the following agents:</u> • Anti-obesity medications • Repatha, Praluent <u>Criteria reviewed and unchanged:</u> • SGLT2 class • Methergine • ICS/LABA <u>CCHP formulary changes were made to the following drugs:</u> • Insulins

• First generation antihistamines • Pradaxa • Opioid containing antitussives	
Guest Speaker(s)	
• None	
<u>CCHP P&T Committee approved the following modifications to the formulary (commercial and BHC members):</u>	
Medication Name & Dosage Strength	Approved Formulary Changes
Ztlido 1.8% patch	Add to formulary with prior authorization
Verzenio (abemaciclib)	
Ibrance (palbociclib)	
Kisqali (ribociclib)	
Elmiron Oral Capsule 100mg	
Insulin aspart U-100 cartridge	Added to formulary Tier 2, quantity limit and age limit
Hydrocodone-homatropin (Hycodan) tablet, solution	
Promethazine-codeine syrup	
Hydrocodone poli-chlorpheniramine (Tussionex) ER susp	
Promethazine-phenylephrine-codeine (Promethazine VC/Codeine) syrup	
Guaifenesin-codeine oral liquid, sol	
Boostrix IM suspension	
Engerix-B Injection suspension	
Ipol Injection	
Menveo IM solution	
Pedvax HIB IM Suspension	
ProQuad SubQ suspension	
Recombivax HB Injection susp	
TDVax IM suspension	
Vaxelis IM Suspension Syringe	
Humulin R U-500	Remove from formulary
Brand Pradaxa 75mg, 150mg capsules	
Arestin Dental (minocycline HCl) Microspheres	
Lantus	Add to formulary

New Product Reviews (including new indications)

- | | |
|---|--|
| • Velsipity (etrasimod) tabs | • Ogsiveo (nirogacestat) 50mg oral tabs |
| • Bimzelx (bimekizumab-bkzx) syringe | • Coxanto (oxaprozin) capsules |
| • Altuviio antihemophilic factor | • Fabhalta (iptacopan) capsules |
| • Omvoh (mirikizumab-mrkz) auto-inj | • Casgevy (exagamglogeneautotemcel) IV suspension |
| • Zepbound (tirzepatide) | • Lyfgenia (lovotibeqlogene autotemcel) intravenous suspension |
| • Rozlytrek (entrectinib) 50mg | • Zituvio (sitagliptin) tablets |
| • Fruzaqla (fruquintinib) capsules | • Zorvyte (roflumilast) 0.3% topical foam |
| • Zurzuvae (zuranolone) oral capsules | • Wainua (eplontersen) auto-injector |
| • Inpefa (sotagliflozin) tabs | • IxchIQ (chikungunya) IM vaccine |
| • Voquezna (vonoprazan) tabs | • Agamree (vamorolone) oral susp |
| • Augtyro (repotrectinib) oral capsules | • Hemlibra (emicizumab-kxwh) 300 subcutaneous vial |
| • Xalkori (crizotinib) oral pellet caps | |
| • Truqap (capivasertib) oral tabs | |
| • Loqtorzi (toripalimab-tpzi) IV vial | |
| • Iwilfin (eflornithine) oral tabs | |